ZNF217 and breast cancer: ZNF217 supports TGF-β signaling through TGF-β2 and TGF-β3 transcriptional activation; interestingly, TGF-β signaling hyperactivation results in ZEB1 overexpression, outlining a possible autocrine ATB-centered regulatory loop that supports trastuzumab resistance and metastasis in BC [219].